Carbometrics secures £1.4m for synthetic glucose-binding molecule technology

Synthetic glucose-binding molecules designed for ultra-accurate continuous metabolic monitoring are the focus of a £1.4m investment into Bristol-based Carbometrics.

The company was incorporated in 2018 to address requirements for data accuracy in clinical settings. Its primary product, i-CAM, is a metabolic monitor specifically intended for organ-perfusion circuits and cardiopulmonary bypass. This technology is aimed at healthcare providers and medical-device manufacturers.

Operations are based at the Science Creates St Philips incubator, where the firm maintains three state-of-the-art laboratories. The team possesses expertise across physical, organic, polymer, material, and analytical chemistry, alongside physics, optoelectronic devices, mechanical engineering, and biochemistry. This approach stems from an R&D history in sensor development and drug discovery, including work previously conducted under the name Ziylo.

Accounts for the year ended 31 July 2025 recorded 16 employees, while LinkedIn data currently lists a headcount of 18. This investment represents the total capital secured by the business during the current calendar year.

In-house competencies extend to sterile assembly, fluidics, and surface characterisation using atomic force microscopy and scanning electron microscopy. Documentation for the round was filed in September 2026, with the allotment of shares taking place earlier that month.